SLC5A2 and type 2 diabetes mellitus: In this sub-analysis from the randomized controlled trial PROTECT (Prevention of Atherosclerosis by SGLT2 Inhibitor: Multicenter, Randomized Controlled Study) for patients with T2DM [23, 24], we sought to examine the effects of the use of the SGLT2 inhibitor ipragliflozin for 24 months on the estimated fluid volume parameters obtained annually for 2 years.